MetaCap

CareDx (CDNA) vs Celcuity (CELC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CareDx (CDNA) has outperformed Celcuity (CELC) over the past year, gaining 307.5% versus a loss of 45.3%. Over five years, CELC leads with a +249.6% price change compared with +65.2% for CDNA. CareDx is the larger company by market cap ($3.68 billion vs $2.61 billion), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDNA+307.45%CELC-45.28%
+438%+185%-68%
Nov 21, 20251 yearNov 20, 2026
CDNA+62.75%CELC+231.99%
+803%+336%-131%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDNA versus CELC key metrics
MetricCDNACELC
Share price$70.00$53.35
Market cap$3.68B$2.61B
1-day change-2.67%-5.26%
YTD return+271.55%-46.51%
1-year return+307.45%-45.28%
5-year return+65.21%+249.61%
P/E ratio (TTM)29.54—
Forward P/E44.75—
EPS (TTM)$2.37$-4.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$379.81M—
Revenue growth (YoY)+13.79%—
Net income (latest FY)$-21.35M$-177.04M
Operating margin-8.10%—
Net margin-5.62%—
52-week high$90.87$151.02
52-week low$15.56$53.20
Distance from 52-week high-22.97%-64.67%
Analyst consensusbuystrong_buy
Avg. price target upside+34.90%+182.76%
Average volume1.30M1.25M
Shares outstanding52.54M48.93M
Employees761155
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CDNA has outperformed CELC by 352.7 percentage points over the past year.

About CareDx

CDNA stock →

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.

Health Care · Medical Specialities · 761 employees

About Celcuity

CELC stock →

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).

Health Care · Medical Specialities · 155 employees

CDNA vs CELC FAQ

Which is bigger, CareDx or Celcuity?

CareDx (CDNA) is larger, with a market capitalization of $3.68B compared with $2.61B for Celcuity (CELC).

Which stock has performed better over the past year, CDNA or CELC?

CDNA returned +307.45% over the past 12 months, compared with -45.28% for CELC (price return, excluding dividends). Past performance does not predict future results.

Are CareDx and Celcuity in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons